Harvey Jones bought GSK shares hoping to bag a solid second income stream while nailing down steady share price growth as well. Sadly, it hasn't turned out that way. The post Down 25% with a 4.32% ...

The World Bank’s ‘one stop shop’ bid to up investment. Plus, we list down the Inter-American Development Bank's top 10 ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Smith from ...

In this Q&A, He discussed Boehringer's investments in AI as well as areas where the technology could deliver greater value for pharma.

MDCX READ THE FULL V.MDCX RESEARCH REPORT IPO in U.S. Provides Additional Funding & Common Stock that Trades on Nasdaq On ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £16.90. The company’s shares opened today at ...

Big Pharma allows millions of people to alleviate debilitating pain, manage dangerous and chronic diseases, mitigate their ...

US health officials have approved vaccines for respiratory syncytial virus (RSV), an infection that can be deadly for some ...

CVS Pharmacy is facing a proposed class-action lawsuit alleging that it misleadingly markets certain over-the-counter medications as "non-drowsy" despite t ...

The global over-the-counter (OTC) pain medication market is poised for steady growth, with its market size expected to attain ...

Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...